{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:42:54Z","timestamp":1784076174433,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Centre hospital universitaire de Saint-Etienne"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03085-3","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T07:13:35Z","timestamp":1742195615000},"page":"646-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of thrombocytopenia and anticoagulant therapy in patients with hematological malignancy on chemotherapy: a binational prospective study (TAT study)"],"prefix":"10.1007","volume":"58","author":[{"given":"Elie","family":"Jalaber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Genthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Daguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Barri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Teste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Daguenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0879-6261","authenticated-orcid":false,"given":"Emilie","family":"Chalayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"3085_CR1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/jcm10061169","volume":"10","author":"A Leader","year":"2021","unstructured":"Leader A, Hofstetter L, Spectre G (2021) Challenges and advances in managing thrombocytopenic cancer patients. J Clin Med 10:1169. https:\/\/doi.org\/10.3390\/jcm10061169","journal-title":"J Clin Med"},{"key":"3085_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1182\/blood.2022016558","volume":"140","author":"SJ Stanworth","year":"2022","unstructured":"Stanworth SJ, Shah A (2022) How i use platelet transfusions. Blood 140:1925\u20131936. https:\/\/doi.org\/10.1182\/blood.2022016558","journal-title":"Blood"},{"key":"3085_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","volume":"380","author":"H Wandt","year":"2012","unstructured":"Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, D\u00f6lken G, Klenner A, H\u00e4nel M, Herbst R, Junghanss C, Ehninger G (2012) Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 380:1309\u20131316. https:\/\/doi.org\/10.1016\/S0140-6736(12)60689-8","journal-title":"Lancet"},{"key":"3085_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1741-7015-10-97","volume":"10","author":"C-Y Chen","year":"2012","unstructured":"Chen C-Y, Tai C-H, Cheng A, Wu H-C, Tsay W, Liu J-H, Chen P-Y, Huang S-Y, Yao M, Tang J-L, Tien H-F (2012) Intracranial hemorrhage in adult patients with hematological malignancies. BMC Med 10:97. https:\/\/doi.org\/10.1186\/1741-7015-10-97","journal-title":"BMC Med"},{"key":"3085_CR5","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, B\u00fcller HR, S\u00f8rensen HT (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137:1959\u20131969. https:\/\/doi.org\/10.1182\/blood.2020007338","journal-title":"Blood"},{"key":"3085_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2007-10-117051","volume":"112","author":"DE Gerber","year":"2008","unstructured":"Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB (2008) The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 112:504\u2013510. https:\/\/doi.org\/10.1182\/blood-2007-10-117051","journal-title":"Blood"},{"key":"3085_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458\u2013464. https:\/\/doi.org\/10.1001\/archinte.166.4.458","journal-title":"Arch Intern Med"},{"key":"3085_CR8","doi-asserted-by":"publisher","unstructured":"Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol 59:7351. https:\/\/doi.org\/10.1200\/JCO.2014.59.7351.","DOI":"10.1200\/JCO.2014.59.7351"},{"key":"3085_CR9","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing G-J, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK (2021) Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160:2247\u20132259. https:\/\/doi.org\/10.1016\/j.chest.2021.07.056","journal-title":"Chest"},{"key":"3085_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000750","volume":"6","author":"A Falanga","year":"2022","unstructured":"Falanga A, Leader A, Ambaglio C, Bagoly Z, Castaman G, Elalamy I, Lecumberri R, Niessner A, Pabinger I, Szmit S, Trinchero A, Ten Cate H, Rocca B (2022) EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 6:e750. https:\/\/doi.org\/10.1097\/HS9.0000000000000750","journal-title":"HemaSphere"},{"key":"3085_CR11","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/jth.15789","volume":"20","author":"J Thachil","year":"2022","unstructured":"Thachil J, Carrier M, Lisman T (2022) Anticoagulation in thrombocytopenic patients\u2014time to rethink? J Thromb Haemost 20:1951\u20131956. https:\/\/doi.org\/10.1111\/jth.15789","journal-title":"J Thromb Haemost"},{"key":"3085_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.acvd.2023.11.009","volume":"117","author":"S Laporte","year":"2024","unstructured":"Laporte S, Benhamou Y, Bertoletti L, Fr\u00e8re C, Hanon O, Couturaud F, Moustafa F, Mismetti P, Sanchez O, Mah\u00e9 I (2024) INNOVTE CAT Working Group, management of cancer-associated thromboembolism in vulnerable population. Arch Cardiovasc Dis 117:45\u201359. https:\/\/doi.org\/10.1016\/j.acvd.2023.11.009","journal-title":"Arch Cardiovasc Dis"},{"key":"3085_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.critrevonc.2018.09.014","volume":"132","author":"A Leader","year":"2018","unstructured":"Leader A, ten Cate H, Spectre G, Beckers EAM, Falanga A (2018) Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps. Crit Rev Oncol Hematol 132:76\u201388. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.09.014","journal-title":"Crit Rev Oncol Hematol"},{"key":"3085_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-0038-1676520","volume":"119","author":"A Leader","year":"2019","unstructured":"Leader A, Ten Cate V, Ten Cate-Hoek A, Spectre G, Beckers E, Raanani P, Giaccherini C, Pereg D, Schouten H, Falanga A, Ten Cate H (2019) Managing anti-platelet therapy in thrombocytopaenic patients with haematological malignancy: a multinational clinical vignette-based experiment. Thromb Haemost 119:163\u2013174. https:\/\/doi.org\/10.1055\/s-0038-1676520","journal-title":"Thromb Haemost"},{"key":"3085_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s11239-021-02393-8","volume":"52","author":"N Livneh","year":"2021","unstructured":"Livneh N, Braeken D, Drozdinsky G, Gafter-Gvili A, Seelig J, Rozovski U, Berger T, Raanani P, Falanga A, Ten Cate H, Spectre G, Leader A (2021) Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy. J Thromb Thrombol 52:590\u2013596. https:\/\/doi.org\/10.1007\/s11239-021-02393-8","journal-title":"J Thromb Thrombol"},{"key":"3085_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Nisio MD, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K (2023) Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline\u2606. Ann Oncol 34:452\u2013467. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014","journal-title":"Ann Oncol"},{"key":"3085_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.rec.2019.03.019","volume":"72","author":"T L\u00f3pez-Fern\u00e1ndez","year":"2019","unstructured":"L\u00f3pez-Fern\u00e1ndez T, Mart\u00edn-Garc\u00eda A, Rold\u00e1n Rabad\u00e1n I, Mitroi C, Maz\u00f3n Ramos P, D\u00edez-Villanueva P, Escobar Cervantes C, Alonso Mart\u00edn C, Alonso Salinas GL, Arenas M, Arrarte Esteban VI, Ayala de La Pe\u00f1a F, Castro Fern\u00e1ndez A, Garc\u00eda Pardo H, Garc\u00eda-Sanz R, Gonz\u00e1lez Porras JR, L\u00f3pez de S\u00e1 E, Lozano T, Marco Vera P, Mart\u00ednez Mar\u00edn V, Mesa Rubio D, Montero \u00c1, Oristrell G, P\u00e9rez de Prado A, Velasco Del Castillo S, Virizuela Echaburu JA, Zatarain-Nicol\u00e1s E, Anguita S\u00e1nchez M, Tamargo Men\u00e9ndez J (2019) Expert reviewers, atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev. Espanola Cardiol. Engl. Ed 72:749\u2013759. https:\/\/doi.org\/10.1016\/j.rec.2019.03.019","journal-title":"Rev. Espanola Cardiol. Engl. Ed"},{"key":"3085_CR18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/trf.14120","volume":"57","author":"E Chalayer","year":"2017","unstructured":"Chalayer E, Cavalieri D, Martignoles JA, Genthon A, Tavernier E, Tardy B (2017) Antithrombotic therapy and platelet transfusions in hematologic malignancy patients presenting chemotherapy-induced thrombocytopenia: a French survey. Transfusion (Paris) 57:1717\u20131723. https:\/\/doi.org\/10.1111\/trf.14120","journal-title":"Transfusion (Paris)"},{"key":"3085_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2023.150751","volume":"37","author":"CL Maier","year":"2023","unstructured":"Maier CL, Stanworth SJ, Sola-Visner M, Kor D, Mast AE, Fasano R, Josephson CD, Triulzi DJ, Nellis ME (2023) Prophylactic platelet transfusion: is there evidence of benefit, harm, or no effect? Transfus Med Rev 37:150751. https:\/\/doi.org\/10.1016\/j.tmrv.2023.150751","journal-title":"Transfus Med Rev"},{"key":"3085_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093\u20131100. https:\/\/doi.org\/10.1378\/chest.10-0134","journal-title":"Chest"},{"key":"3085_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263\u2013272. https:\/\/doi.org\/10.1378\/chest.09-1584","journal-title":"Chest"},{"key":"3085_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1056\/NEJMoa0904084","volume":"362","author":"SJ Slichter","year":"2010","unstructured":"Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600\u2013613. https:\/\/doi.org\/10.1056\/NEJMoa0904084","journal-title":"N Engl J Med"},{"key":"3085_CR23","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/jth.15748","volume":"20","author":"S Booth","year":"2022","unstructured":"Booth S, HaemSTAR Network M, Desborough N, Curry S. Stanworth (2022) Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort. J Thromb Haemost. JTH 20:1830\u20131838. https:\/\/doi.org\/10.1111\/jth.15748","journal-title":"J Thromb Haemost JTH"},{"key":"3085_CR24","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/jth.14576","volume":"17","author":"B Tardy","year":"2019","unstructured":"Tardy B, Chalayer E, Kamphuisen PW, Ni Ainle F, Verhamme P, Varlet MN, Chauleur C, Rodger M, Merah A, Buchmuller A, Bistervels I, De Sancho MT, Middeldorp S, Bertoletti L (2019) SSC Subcommittee on Control of Anticoagulation of the ISTH, Definition of bleeding events in studies evaluating prophylactic antithrombotic therapy in pregnant women: a systematic review and a proposal from the ISTH SSC. J Thromb Haemost JTH 17:1979\u20131988. https:\/\/doi.org\/10.1111\/jth.14576","journal-title":"J Thromb Haemost JTH"},{"key":"3085_CR25","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","volume":"5","author":"BJ Carney","year":"2021","unstructured":"Carney BJ, Wang T-F, Ren S, George G, Al Homssi A, Gaddh M, Connolly GC, Shah VI, Bogue T, Bartosic A, Neuberg D, Baumann Kreuziger L, Zwicker JI, Network Investigators VENUS (2021) Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv 5:5546\u20135553. https:\/\/doi.org\/10.1182\/bloodadvances.2021005966","journal-title":"Blood Adv"},{"key":"3085_CR26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archinte.1993.00410130045005","volume":"153","author":"G Simonneau","year":"1993","unstructured":"Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S (1993) Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 153:1541\u20131546","journal-title":"Arch Intern Med"},{"key":"3085_CR27","first-page":"189","volume":"16","author":"H Partsch","year":"1997","unstructured":"Partsch H, Kechavarz B, K\u00f6hn H, Mostbeck A (1997) The effect of mobilisation of patients during treatment of thromboembolic disorders with low-molecular-weight heparin. Int Angiol J Int Union Angiol 16:189\u2013192","journal-title":"Int Angiol J Int Union Angiol"},{"key":"3085_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7326\/M21-2981","volume":"175","author":"G Le Gal","year":"2022","unstructured":"Le Gal G, Kovacs MJ, Bertoletti L, Couturaud F, Dennie C, Hirsch AM, Huisman MV, Klok FA, Kraaijpoel N, Mallick R, Pecarskie A, Pena E, Phillips P, Pichon I, Ramsay T, Righini M, Rodger MA, Roy P-M, Sanchez O, Schmidt J, Schulman S, Shivakumar S, Trinh-Duc A, Verdet R, Vinsonneau U, Wells P, Wu C, Yeo E, Carrier M, Investigators SSPE (2022) Risk for recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation: a multicenter prospective cohort study. Ann Intern Med 175:29\u201335. https:\/\/doi.org\/10.7326\/M21-2981","journal-title":"Ann Intern Med"},{"key":"3085_CR29","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.jcin.2016.08.039","volume":"9","author":"M Mellado","year":"2016","unstructured":"Mellado M, Pijoan JI, Jim\u00e9nez D, Muriel A, Aujesky D, Bertoletti L, Decousus H, Barrios D, Clar\u00e1 A, Yusen RD, Monreal M (2016) RIETE investigators, outcomes associated with inferior vena cava filters among patients with thromboembolic recurrence during anticoagulant therapy. JACC Cardiovasc Interv 9:2440\u20132448. https:\/\/doi.org\/10.1016\/j.jcin.2016.08.039","journal-title":"JACC Cardiovasc Interv"},{"key":"3085_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjcard.2023.06.068","volume":"202","author":"S Kumar","year":"2023","unstructured":"Kumar S, Yoon S, Milioglou I, Tashtish N, Farmakis I, Dallan LAP, Mogalapalli A, Arruda M, Filby SJ (2023) Left atrial appendage closure outcomes in patients with cancer at a single tertiary center. Am J Cardiol 202:176\u2013181. https:\/\/doi.org\/10.1016\/j.amjcard.2023.06.068","journal-title":"Am J Cardiol"},{"key":"3085_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jaccao.2022.08.014","volume":"5","author":"A Leader","year":"2023","unstructured":"Leader A, Mendelson Cohen N, Afek S, Jaschek R, Frajman A, Itzhaki Ben Zadok O, Raanani P, Lishner M, Spectre G (2023) Arterial thromboembolism in patients with AF and CHA2DS2-VASc Score 0\u20132 with and without cancer. JACC CardioOncology 5:174\u2013185. https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.014","journal-title":"JACC CardioOncology"},{"key":"3085_CR32","doi-asserted-by":"publisher","unstructured":"Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AGG, Hasselblad V, Ortel TL (2015) Perioperative bridging anticoagulation in patients with atrial fibrillation. https:\/\/doi.org\/10.1056\/NEJMoa1501035.","DOI":"10.1056\/NEJMoa1501035"},{"key":"3085_CR33","doi-asserted-by":"publisher","unstructured":"Teppo K, Lip GYH, Airaksinen KEJ, Halminen O, Haukka J, Putaala J, Mustonen P, Linna M, Hartikainen J, Lehto M (2024) Comparing CHA2DS2-VA and CHA2DS2-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur, 43. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100967.","DOI":"10.1016\/j.lanepe.2024.100967"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03085-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03085-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03085-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:25:41Z","timestamp":1749468341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03085-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["3085"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03085-3","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"24 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"During the preparation of this work the authors used ChatGPT for the graphical abstract. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies"}}]}}